Search

Your search keyword '"D. Charlety"' showing total 9 results
Start Over Author "D. Charlety"
9 results on '"D. Charlety"'

2. Long-Term Survivor with Intrathecal and Intravenous Trastuzumab Treatment in Metastatic Breast Cancer

Author

H. Pluchart, E. Jacquet, Benoît Allenet, D. Charlety, M. Mousseau, Pierrick Bedouch, Pôle Pharmacie [CHU Grenoble Alpes], Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Centre Hospitalier Universitaire Grenoble Alpes (CHU Grenoble Alpes), Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF), Techniques pour l'Evaluation et la Modélisation des Actions de la Santé (TIMC-IMAG-ThEMAS), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Techniques pour l'Evaluation et la Modélisation des Actions de la Santé [2016-2019] (TIMC-ThEMAS [2016-2019]), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 [2016-2019] (TIMC [2016-2019]), Institut polytechnique de Grenoble - Grenoble Institute of Technology [2007-2019] (Grenoble INP [2007-2019])-IMAG-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology [2007-2019] (Grenoble INP [2007-2019])-IMAG-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Domaines Océaniques (LDO), Centre National de la Recherche Scientifique (CNRS)-Institut d'écologie et environnement-Observatoire des Sciences de l'Univers-Université de Brest (UBO)-Institut national des sciences de l'Univers (INSU - CNRS), and Institut national des sciences de l'Univers (INSU - CNRS)-Université de Brest (UBO)-Observatoire des Sciences de l'Univers-Institut d'écologie et environnement-Centre National de la Recherche Scientifique (CNRS)

Subjects
Adult, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, [SHS.EDU]Humanities and Social Sciences/Education, [SHS.PSY]Humanities and Social Sciences/Psychology, Antineoplastic Agents, Breast Neoplasms, Lapatinib, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Cerebrospinal fluid, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, Trastuzumab, Internal medicine, medicine, Humans, Pharmacology (medical), Survivors, Neoplasm Metastasis, skin and connective tissue diseases, neoplasms, ComputingMilieux_MISCELLANEOUS, Chemotherapy, business.industry, medicine.disease, Metastatic breast cancer, 3. Good health, Hormone receptor, 030220 oncology & carcinogenesis, Administration, Intravenous, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, 030217 neurology & neurosurgery, Mastectomy, medicine.drug
Abstract

We report the case of a woman with metastatic breast cancer receiving intrathecal trastuzumab (and intravenous trastuzumab for more than 7 years). She was diagnosed in 2001 with a duct invasive breast cancer T3N1M0 HER2 (human epidermal growth factor receptor 2)-positive +++ HR (hormone receptor) -negative. She received chemotherapy and then she had a mastectomy. Several metastases were discovered and treated from 2003 to 2008 with chemotherapy. In March 2010, brain metastases and a leptomeningeal carcinomatosis from her HER2-positive breast cancer appeared. From that moment on she received intravenous trastuzumab (6 mg/kg) every 3 weeks, intrathecal trastuzumab (21 mg) weekly for 16 injections and lapatinib. Intrathecal trastuzumab was stopped because of cerebrospinal fluid (CSF) clearing. Intrathecal trastuzumab was injected again from December 2013 for 14 injections. The relevance of treating leptomeningeal carcinomatosis with intrathecal trastuzumab administration is shown through this case report.

Published
2016
Full Text
View/download PDF

3. Quelles attentes des patients souffrant de cancers en hôpital de jour en termes d’information sur leur traitement ?

Author

J. Calop, J.-Y. Cahn, E. Franchon, Benoît Allenet, M. Laramas, B. Pégourié, V. Lamy, C. Rebischung, D. Charlety, and C. Rey

Subjects
Gynecology, medicine.medical_specialty, business.industry, medicine, Outpatient clinic, Pharmacology (medical), business
Abstract

Resume Objectif Un guide d’entretien base sur les donnees de la litterature a ete redige afin de recueillir les attentes des patients cancereux en termes d’information concernant leur prise en charge therapeutique. Patients et methodes Trente-quatre patients recevant une chimiotherapie intraveineuse en hopital de jour d’oncologie-hematologie, selectionnes selon la technique dite des choix raisonnes, ont accepte de realiser un entretien avec un pharmacien selon un mode semi-directif. Resultats Les patients sont globalement satisfaits de l’information recue. Trois-quarts des patients expriment des attentes concernant l’organisation de leur prise en charge, et notamment sur l’acces a une information personnalisee. Les attentes specifiques aux traitements medicamenteux sont essentiellement liees a la gestion des effets indesirables : 72 % des patients declarent que leur qualite de vie est affectee par les effets indesirables (principalement fatigue, douleurs et troubles digestifs). L’utilisation de medecines alternatives et complementaires est rapportee par quatre patients. Conclusion Les attentes mises en evidence concernant les traitements medicamenteux justifient la construction d’un dispositif de suivi personnalise assure par un pharmacien au sein de l’hopital de jour.

Published
2010
Full Text
View/download PDF

7. PCN23 PHARMACOEPIDEMIOLOGY OF PATIENTS TREATED WITH TEMOZOLOMIDE

Author

F. Pinguet, M Billard, C Schlemmer, P. Tilleul, Isabelle Borget, D Charlety, E Raingeard, MN Lefebre, V Bertholle, Yasmine Hassani, R Chevrier, Michel Fabbro, C Audeval, M. Daouphars, and M Brignone

Subjects
Oncology, medicine.medical_specialty, Temozolomide, business.industry, Health Policy, Internal medicine, Public Health, Environmental and Occupational Health, medicine, Pharmacoepidemiology, urologic and male genital diseases, business, female genital diseases and pregnancy complications, medicine.drug
Published
2009
Full Text
View/download PDF

8. Long-Term Survivor with Intrathecal and Intravenous Trastuzumab Treatment in Metastatic Breast Cancer.

Author

Pluchart H, Jacquet E, Charlety D, Allenet B, Bedouch P, and Mousseau M

Subjects
Administration, Intravenous, Adult, Antineoplastic Agents administration & dosage, Antineoplastic Agents pharmacology, Breast Neoplasms mortality, Breast Neoplasms pathology, Female, Humans, Neoplasm Metastasis, Survivors, Trastuzumab administration & dosage, Trastuzumab pharmacology, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Trastuzumab therapeutic use
Abstract

We report the case of a woman with metastatic breast cancer receiving intrathecal trastuzumab (and intravenous trastuzumab for more than 7 years). She was diagnosed in 2001 with a duct invasive breast cancer T3N1M0 HER2 (human epidermal growth factor receptor 2)-positive +++ HR (hormone receptor) -negative. She received chemotherapy and then she had a mastectomy. Several metastases were discovered and treated from 2003 to 2008 with chemotherapy. In March 2010, brain metastases and a leptomeningeal carcinomatosis from her HER2-positive breast cancer appeared. From that moment on she received intravenous trastuzumab (6 mg/kg) every 3 weeks, intrathecal trastuzumab (21 mg) weekly for 16 injections and lapatinib. Intrathecal trastuzumab was stopped because of cerebrospinal fluid (CSF) clearing. Intrathecal trastuzumab was injected again from December 2013 for 14 injections. The relevance of treating leptomeningeal carcinomatosis with intrathecal trastuzumab administration is shown through this case report.

Published
2016
Full Text
View/download PDF

9. A multicenter prospective observational study of the conformity of temozolomide prescriptions in France.

Author

Tilleul P, Brignone M, Hassani Y, Labrande C, Pedeboscq S, Gensollen S, Lahille B, Exinger D, Bertholle V, Billard M, Charlety D, Prebay D, Pinguet F, Taillibert S, Cartalat S, Chinot O, and Borget I

Subjects
Antineoplastic Agents, Alkylating therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dacarbazine administration & dosage, Dacarbazine therapeutic use, Drug Administration Schedule, Drug Utilization, Female, France, Humans, Male, Middle Aged, Practice Patterns, Physicians', Prospective Studies, Temozolomide, Antineoplastic Agents, Alkylating administration & dosage, Dacarbazine analogs & derivatives, Glioma drug therapy, Guideline Adherence statistics & numerical data, Off-Label Use statistics & numerical data, Practice Guidelines as Topic
Abstract

Context: Temozolomide (TMZ) is approved for the treatment of high-grade gliomas such as glioblastoma (GBM) multiforme and refractory anaplastic astrocytoma, but it is also used in indications not mentioned in the summary of product characteristics (SPC). The main objective of this study was to evaluate the conformity of TMZ prescriptions to the French SPC and prescription guidebook., Methods: We conducted a prospective observational study of all consecutive patients treated with TMZ in 21 French hospitals between September 2006 and February 2007, accounting for 39% of total TMZ consumption in France. The conformity of TMZ prescriptions was evaluated in terms of the indication, dosage, treatment duration, and combination with other treatments, with respect to the SPC and prescription guidebook., Results: We enrolled 831 patients (median age, 56 years) who received a total of 5982 TMZ treatment cycles. TMZ was mainly prescribed to patients with newly diagnosed GBM (384 patients), GBM in progression/relapse (28 patients), or anaplastic astrocytoma in progression/relapse (19 patients). Prescriptions conformed to the SPC in 51.9% of cases and to the prescription guidebook in 91.5% of cases. Global conformity with the SPC, in terms of the dosage, treatment duration, and combination with other treatments, was 62% for newly diagnosed GBM treated with radiotherapy plus TMZ, 72% for TMZ maintenance monotherapy, and 66% for GBM and anaplastic astrocytoma in progression/relapse., Conclusion/discussion: In France, routine TMZ prescriptions conform to the SPC and practice guidebook. This is one of the largest studies of drug use in neuro-oncology in terms of the number of patients and cycles analyzed., (Copyright © 2012 John Wiley & Sons, Ltd.)

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results